Harvard Bioscience (HBIO) Competitors

Thermo Fisher Scientific (NYSE:TMO) and Harvard Bioscience (NASDAQ:HBIO) are both life sciences tools & services companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment.

Is TMO or HBIO more profitable?

Thermo Fisher Scientific has a net margin of 15.24% compared to Harvard Bioscience's net margin of -64.68%. Thermo Fisher Scientific's return on equity of 16.82% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Thermo Fisher Scientific	15.24%	16.82%	8.38%
Harvard Bioscience	-64.68%	-5.64%	-2.15%

Which has more risk and volatility, TMO or HBIO?

Thermo Fisher Scientific has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, Harvard Bioscience has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500.

Do institutionals and insiders believe in TMO or HBIO?

89.2% of Thermo Fisher Scientific shares are owned by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are owned by institutional investors. 0.3% of Thermo Fisher Scientific shares are owned by company insiders. Comparatively, 9.5% of Harvard Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Which has higher valuation and earnings, TMO or HBIO?

Thermo Fisher Scientific has higher revenue and earnings than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Thermo Fisher Scientific	$42.88B	4.22	$6.34B	$17.29	27.73
Harvard Bioscience	$94.14M	0.21	-$12.40M	-$1.30	-0.34

Do analysts prefer TMO or HBIO?

Thermo Fisher Scientific currently has a consensus price target of $592.24, indicating a potential upside of 23.52%. Harvard Bioscience has a consensus price target of $2.00, indicating a potential upside of 352.90%. Given Harvard Bioscience's higher possible upside, analysts clearly believe Harvard Bioscience is more favorable than Thermo Fisher Scientific.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Thermo Fisher Scientific	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.77
Harvard Bioscience	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Does the media favor TMO or HBIO?

In the previous week, Thermo Fisher Scientific had 61 more articles in the media than Harvard Bioscience. MarketBeat recorded 69 mentions for Thermo Fisher Scientific and 8 mentions for Harvard Bioscience. Thermo Fisher Scientific's average media sentiment score of 1.26 beat Harvard Bioscience's score of 0.30 indicating that Thermo Fisher Scientific is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Thermo Fisher Scientific	46 Very Positive mention(s)	8 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Harvard Bioscience	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Thermo Fisher Scientific beats Harvard Bioscience on 13 of the 16 factors compared between the two stocks.